Title: Nanoparticles for therapy and diagnosis of Alzheimer disease
EU FP7 Large Scale Collaborative project
Participant's number: 19
Role: partner, administrative project manager
Project number: NMP4-LA-2008-212043
Project website: http://www.nadproject.eu/
Objectives: The aim of this project is to utilize nanoparticles (NPs) specifically engineered for targeting brain Aß, for the combined diagnosis and therapy (theranostics) of AD. NPs (liposomes, solid lipid NPs, polymeric-NPs) will be multiple-functionalized with: i) a large arsenal of molecules (specific lipids, antiamyloidogenic drugs, polyphenols, heteroaromatic compounds, unnatural peptides and peptidomimetics, antibodies) interacting with Aß in all aggregation forms, ii) PET or MRI contrast agents detecting such interaction, iii) molecules stimulating BBB crossing via the transcytotic route. Several artificial and cellular models will be used to fine-tune such features and to improve NPs biocompatibility, non-immunogenicity, non-toxicity and physical stability. Eventually, absorption, distribution, metabolism and excretion will be studied using animal models of AD. Different routes (i.v., oral, nasal) and protocols (two-step, NPs cocktails, aerosols) of administration will be utilized to boost NPs brain delivery. The prediction is that NPs will detect, disaggregate and remove Aß brain deposits. In any case, NPs will interact with blood Aß, withdrawing the excess of brain peptide by a "sink" effect.